Literature DB >> 34936867

Species-selective targeting of pathogens revealed by the atypical structure and active site of Trypanosoma cruzi histone deacetylase DAC2.

Martin Marek1, Elizabeth Ramos-Morales1, Gisele F A Picchi-Constante2, Theresa Bayer3, Carina Norström4, Daniel Herp5, Policarpo A Sales-Junior6, Eloise P Guerra-Slompo2, Kristin Hausmann3, Alokta Chakrabarti5, Tajith B Shaik1, Annika Merz5, Edouard Troesch1, Karin Schmidtkunz5, Samuel Goldenberg2, Raymond J Pierce7, Marina M Mourão6, Manfred Jung5, Johan Schultz4, Wolfgang Sippl3, Nilson I T Zanchin8, Christophe Romier9.   

Abstract

Writing and erasing of posttranslational modifications are crucial to phenotypic plasticity and antigenic variation of eukaryotic pathogens. Targeting pathogens' modification machineries, thus, represents a valid approach to fighting parasitic diseases. However, identification of parasitic targets and the development of selective anti-parasitic drugs still represent major bottlenecks. Here, we show that the zinc-dependent histone deacetylases (HDACs) of the protozoan parasite Trypanosoma cruzi are key regulators that have significantly diverged from their human counterparts. Depletion of T. cruzi class I HDACs tcDAC1 and tcDAC2 compromises cell-cycle progression and division, leading to cell death. Notably, tcDAC2 displays a deacetylase activity essential to the parasite and shows major structural differences with human HDACs. Specifically, tcDAC2 harbors a modular active site with a unique subpocket targeted by inhibitors showing substantial anti-parasitic effects in cellulo and in vivo. Thus, the targeting of the many atypical HDACs in pathogens can enable anti-parasitic selective chemical impairment.
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Trypanosoma cruzi; atypical three-dimensional structure; chemical inhibition; eukaryotic parasites; functional essentiality; histone deacetylases

Mesh:

Substances:

Year:  2021        PMID: 34936867     DOI: 10.1016/j.celrep.2021.110129

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  3 in total

1.  Effects of Structurally Different HDAC Inhibitors against Trypanosoma cruzi, Leishmania, and Schistosoma mansoni.

Authors:  Elisabetta Di Bello; Beatrice Noce; Rossella Fioravanti; Clemens Zwergel; Sergio Valente; Dante Rotili; Giulia Fianco; Daniela Trisciuoglio; Marina M Mourão; Policarpo Sales; Suzanne Lamotte; Eric Prina; Gerald F Späth; Cécile Häberli; Jennifer Keiser; Antonello Mai
Journal:  ACS Infect Dis       Date:  2022-06-22       Impact factor: 5.578

2.  Efficient CRISPR-Cas9-mediated genome editing for characterization of essential genes in Trypanosoma cruzi.

Authors:  Gisele Fernanda Assine Picchi-Constante; Priscila Mazzocchi Hiraiwa; Martin Marek; Vanessa Zulkievicz Rogerio; Eloise Pavão Guerra-Slompo; Christophe Romier; Nilson Ivo Tonin Zanchin
Journal:  STAR Protoc       Date:  2022-04-21

Review 3.  Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis.

Authors:  Ehab Ghazy; Mohamed Abdelsalam; Dina Robaa; Raymond J Pierce; Wolfgang Sippl
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.